Chairs: Heidi Klepin (US), Nina Neuendorff (DE)
09:00-09:12 – O17: Decision model for treatment of aml patients aged 70 and older. External validation in a large institutional cohort – Martine Extermann (US)
09:12-09:15 – Discussion and questions
09:15-09:27 – O18: Cognitive impairment, hypoalbuminemia, high CRP and past history of gastro-intestinal ulcer: 4 markers of frailty which identify patients with malignant hemopathies who don’t benefit from standard dose chemotherapy – Stéphanie Dubruille (BE)
09:27-09:30 – Discussion and questions
09:30-09:42 – O19: Frailty predicts survival and toxicity in newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation; report of the hovon-87/NMSG-18 study group – Claudia Stege (NL)
09:42-09:45 – Discussion and questions
09:45-09:57 – O20: Functional status is associated with outcomes after allogeneic stem cell transplantation for older patients with hematologic malignancies – Li-Wen Huang (US)
09:57-10:00 – Discussion and questions